Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes’ stage C or D

Ji-Cheng Zhang, Zuo-Ren Wang, Yan-Juan Cheng, Ding-Zhong Yang, Jing-Sen Shi, Ai-Lin Liang, Ning-Na Liu, Xiao-Min Wang

INTRODUCTION
Colorectal carcinoma appears to be increasing in Chinese populations and is characterised by an aggressive course and frequent metastases resulting in death. To reduce morbidity and mortality, identification of those patients with a high propensity to develop distant metastases is of great importance, since they might benefit from adjuvant chemotherapy and/or radiotherapy\cite{11,12}. Although Dukes’ classification is still considered as the most accurate predictor of prognosis after resection, even within a group of tumors of a specified stage, tumor behaviour and prognosis of the disease is not uniform\cite{3,5}. For this reason, additional markers that predict tumor metastatic behaviour are needed\cite{6,9}. At present, PCNA has been described as a significant factor in the prognosis of colorectal carcinoma in several studies\cite{10,12}. On the other hand, many studies demonstrated that expression of CD44v6 correlated with poor survival and was an independent prognostic factor in patients with Dukes’ stage C or D\cite{13,17}. However, to our knowledge questions concerning metastases, characteristic changes that occur during the metastatic process, and the correlation between tumor characteristics have to be clarified in detail\cite{18,20}. To our knowledge, there has been neither any study regarding patients with Dukes’ stage C or D analyzing both primary sites and corresponding metastatic lymph nodes genetically or immunohistologically nor a study assessing their relationship.

We examined the expression of these two factors in both primary sites and metastatic lymph nodes to elucidate the characteristic changes of the tumor during metastases and to evaluate the correlation between cell proliferation activity and metastatic ability of the tumor in patients with Dukes’ stage C or D of colorectal carcinoma.

MATERIALS AND METHODS

Materials
175 consecutive patients with colorectal carcinoma admitted to our department underwent resection between 1989 and 1996. The total rate of lymph node metastasis was 33.7 %, 77.2 %, of which lymph node metastasis next to the colorectum was, 17.9 % and 4.9 % mesenteric and mesenteric artery ligation point respectively. Of these 175 patients, 62 (35.8 %) were diagnosed with Dukes’ stage C or D. Among these 62 patients, 56 whose primary site and metastatic node tissues were immunohistochemically evaluable were enrolled in the study. They were comprised of 30 males and 26 females with a mean age of 51.3±14.2 years. Forty nine patients with Dukes’ stage C underwent a complete tumor resection with lymph node dissection and 7 patients with Dukes’ stage D underwent a palliative tumor resection with lymph node dissection in the Department of Gastroenterology, Shannxi Provincial Cancer Hospital in Xi’an, China. The patients had not been treated before. Their respective clinical data were collected through the review of their medical records. Histologic typing revealed 12 papillary adenocarcinomas, 27 tubular adenocarcinomas, 10 mucinous adenocarcinomas, 5 signet-ring cell carcinomas.
and 2 undifferentiated carcinomas. Of these patients, there were 49 patients with Dukes’ stage C, whose average number of metastatic lymph nodes was 5.3±2.1 and 7 patients with Dukes’ stage D, whose average number of metastatic sites including lymph node, liver, greater omentum and peritoneum was 8.7±2.6. The paraffin-embedded blocks and histological slides were taken from the Department of Pathology, Shaanxi Provincial Cancer Hospital (Table 1).

**Table 1** Characteristics of patients with Dukes’ stage C or D colorectal carcinoma

| Gender     | Male | Female |
|------------|------|--------|
| Age (yrs)  | 51 ± 7 | 53 ± 4.2 |
| Histology  | Papillary adenocarcinoma | 12 |
|           | Tubular adenocarcinoma | 27 |
|           | Mucinous adenocarcinoma | 10 |
|           | Signet-ring cell carcinoma | 5 |
|           | Undifferentiated carcinoma | 2 |
| Dukes’ classification | Stage C | 49 |
|           | Stage D | 7 |

**Methods**

Formalin fixed, paraffin embedded sections of samples were stained immunohistochemically with labeled streptavidin-biotin (LSAB) using a LSAB Kit (Doctor Biotechnology Company, Wuhan, Hubei Province, China). The samples were thinly sectioned (4 μm thick). After deparaffinization, the sections were hydrolyzed with ethanol and endogenous peroxidase activity was inhibited with 0.3 % hydrogen peroxide-containing methanol at room temperature for 15 minutes. For antigen retrieval, the sections were mounted in 300 mL 0.01 M sodium citrate buffer (pH 6.0) in a container and microwaved for 15 minutes at maximum power in a Sharp microwave oven (850 W). Nonspecific binding sites were blocked with 10 % nonimmune goat serum. For PCNA, PC10 (Zymed Laboratories, California) whose optimal dilution was 1:150 was used for the first antibody and allowed to react at 4 °C for 12 hours. For CD44v6, CD44 variant exon 6 (VF-18; Bender Co.) whose optimal dilution was 1:100 was used for the first antibody and allowed to react at 4 °C for 12 hours. After the second antibody was made to react, peroxidase-labeled streptavidin was finally allowed to react as an enzyme reagent. Diaminobenzidine was used for coloring. Sections of human tonsils and submucosal lymphoid follicles were used as positive control for PCNA. Positive control of CD44v6 was normal human stratified squamous epithelium which could be strongly stained by anti-CD44v6 antibodies[13]. Sections stained by omitting the primary antibody were used as their negative controls. At least 5 visual fields of the immunohistochemically stained sample were observed at random at x100 or x400 magnification. More than 1000 tumor cells were counted by two investigators who were blinded to the clinical outcome. The number of positive cells was counted and expressed as percentage. For PCNA, when the percentage of positive cells was ≤50 %, the specimen was diagnosed as negative, and when >50 %, the specimen was diagnosed as positive. We also determined the percentage of cells positively stained for CD44v6, as well as the intensity of this staining. Negative, ≤10 % of cells were positively stained, and positive, >10 % cells were positively stained[14]. The data were analyzed using χ² text and a P value <0.05 was considered significant.

**RESULTS**

Immunohistochemical staining with PCNA showed a selective nuclear pattern (Figures 1,2). Thirty-one of 56 patients (55.4 %) expressed PCNA in the primary site and 36 of 56 patients (64.3 %) expressed PCNA in the metastatic lymph node. Among these 56 patients, twenty-four expressed PCNA in both the primary site and metastatic lymph node, seven patients expressed PCNA in the primary site but did not express it in the metastatic lymph node, whereas twelve patients did not express PCNA in the primary site but expressed it in the metastatic lymph node, thirteen patients expressed PCNA in neither the primary site nor metastatic lymph node (Table 2). For expression of PCNA in these 56 patients, a significant relation was observed between the primary site and the metastatic lymph node (0.010< P<0.025).

**Table 2** Expression of PCNA in colorectal carcinoma at primary sites and metastatic lymph nodes

| Metastatic lymph nodes | Primary sites |
|------------------------|--------------|
| -                      | +            |
| -                      | 13           |
| +                      | 12           |
| +                      | 24           |

Note: χ²=5.21, 0.010<P<0.025.

Intensely positive staining with CD44v6 mainly occurred on the cell membrane surface of tumor cells (Figure 3). Forty-one of 56 patients (73.2 %) expressed CD44v6 in the primary site and 39 of 56 patients (69.6 %) expressed CD44v6 in the metastatic lymph node (Figure 4). Among these 56 patients, thirty-three expressed CD44v6 in both the primary site and metastatic lymph node, eight expressed CD44v6 in the primary site but did not express it in the metastatic lymph node, whereas six did not express CD44v6 in the primary site but expressed it in the metastatic lymph node, nine expressed CD44v6 in neither primary site nor metastatic lymph node (Table 3). For expression of CD44v6 in these 56 patients, there was also an significant relationship between the primary site and the metastatic lymph node (0.005<P<0.010).

**Table 3** Expression of CD44v6 in colorectal carcinoma at primary sites and metastatic lymph nodes

| Metastatic lymph nodes | Primary sites |
|------------------------|--------------|
| -                      | +            |
| -                      | 9            |
| +                      | 6            |
| +                      | 33           |

Note: χ²=6.71, 0.005<P<0.010.

**Table 4** Expression of PCNA and CD44v6 in colorectal carcinoma at primary sites

| PCNA | CD44v6 |
|------|--------|
| -    | +      |
| -    | 5      |
| +    | 10     |

Note: χ²=1.06, 0.250<P<0.500.

To evaluate the correlation between cell proliferation activity and metastatic ability, we studied expression of PCNA and CD44v6 in the primary site. Among these 56 patients, twenty-one expressed both PCNA and CD44v6 and 5 expressed neither PCNA nor CD44v6 in the primary site, twenty expressed CD44v6 but did not express PCNA, whereas ten did not express CD44v6 but expressed PCNA in the primary site (Table 4).
No difference was observed between expression of CD44v6 and PCNA in the primary site (0.250 < \( P < 0.500 \)).

**Cell morphology**

Immunohistochemical staining with PCNA showed a selective nuclear pattern (Figures 1, 2). Intensely positive staining with CD44v6 mainly occurred on the cell membrane surface of tumor cells (Figure 3). Expression of CD44v6 in corresponding metastatic lymph node showed that tumor cells were invading lymph node from periphery (Figure 4).

**DISCUSSION**

One of the first steps in multistage colonic carcinogenesis is increased cell proliferation. PCNA, which is a nonhistone nuclear protein of 36 kilodaltons, also is known as cyclin and an auxiliary factor in DNA polymerase, plays a very important role in DNA replication\[22\]. Because of this direct relation with cell proliferation, PCNA is considered to be an important factor in prognosis. In fact, it has been described as a significant factor in the prognosis of colorectal carcinoma in several studies\[10-12\]. CD44, a glycoprotein of the membrane penetration type, functions as an extracellular matrix glycan receptor and a hyaluronate receptor\[23\]. As a consequence of studies in rats showed that CD44v6 could confer metastatic potential to rat pancreatic carcinoma cell lines\[24\], studies addressing the prognostic and biological significance of CD44 variant expression in human cancer have largely been focused on CD44v6. Overexpression of CD44v6 has been demonstrated in colorectal neoplasia by immunohistochemistry, RT-PCR and *in situ* hybridization. Their expression was found to correlate with tumor stage\[13-17\]. As for prognosis, it was shown that expression of CD44v6 correlate with poor survival rate and was an independent prognosticator in patients who underwent radical surgery. Hence, it identifies individuals with a high propensity to develop metastases. These patients might benefit from adjuvant therapy\[16\].

Despite intensive research in recent years, very little is known about the characteristic changes of malignant colorectal tumor cells during the process of metastases. We examined expression of these two factors in both primary site and metastatic lymph node. Among these 56 patients, twenty-four expressed PCNA in both the primary site and metastatic lymph node and thirteen expressed PCNA in neither the primary site nor metastatic lymph node. The concordence rate of PCNA expression in the primary site and in the metastatic lymph node was 66.1 % (0.010 < \( P < 0.025 \)). That is to say, compared with primary site, PCNA expression in metastatic lymph node had no significant change. This suggests that cell proliferation activity revealed by PCNA still exists in the tumor cells of metastatic lymph nodes. Similarly, the concordence rate of CD44v6 expression in the primary site and in the metastatic lymph node was 75.0 % (0.005 < \( P < 0.010 \)). This also means that metastatic ability revealed by CD44v6 still exists in the tumor cells of metastatic lymph nodes.

Although cell proliferation and metastasis are a very complicated problem involving many molecular mechanisms and biologic factors, our study partially showed that tumor cells in metastatic lymph node of colorectal carcinoma still possessed cell proliferation activity and metastatic ability of tumor cells in primary site. However, Kimball *et al.*\[25\] isolated a cellular subpopulation from a human colonic carcinoma cell line and Brattain *et al.*\[26\] reported that malignant cells from a human colonic carcinoma possessed heterogeneity. A question rises: do tumor cells of colorectal carcinoma not possess heterogeneity between the primary site and the metastatic lymph node? It is well known that cancer cell population, either as a solid tumor mass in vivo or as a continuous cell line in vitro, is an ever-changing entity due to their genetic instability and selective environmental pressure. A tumor mass consists of different cell clones, a phenomenon known as tumor
heterogeneity.[27,28] Based on this phenomenon, tumor cell clones with different biological properties have been isolated from a number of human and animal tumor cell lines. The differences included a variety of biological characteristics such as tumor cell morphology, karyotypes, in vitro and in vivo growth patterns.[20,23] DNA ploidy,[21] tumorigenicity, metastatic patterns and metastatic potentials.[22] Cancer metastasis is the ultimate display of complex interactions between the malignant cells and the host defense mechanism. The process of metastasis consists of selection and sequential steps that include angiogenesis, detachment, motility, invasion of the extracellular matrix, intravasation, circulation, adhesion, extravasation into the organ parenchyma and growth.[20] The ability of cancer cells to form metastasis depends on a set of unique biological properties that enable the malignant cells to complete all those steps of metastatic cascade. But this basically biological theory is not in contradiction with our present study, because our results are a clinicopathologic outcome depending upon experiment.

Our study showed that there was no significant association between expression of CD44v6 and PCNA in the primary site (0.250 < P < 0.500). This result partially indicated that there existed no absolute association between cell proliferation activity and metastatic ability in colorectal carcinoma. At present, whether tumor cell growth rate is directly related to metastasis is not clear yet. Yasoshima et al.[25] using metastatic gastric cancer cell line, and Samiei et al.[26] using metastatic mammary clones found that metastasis was independent of tumor cell growth, while other works[27-29] showed a close association between tumor cell growth rate and metastasis. Further study of the correlation between cell proliferation activity and metastatic ability in colorectal carcinoma is therefore needed.

In conclusion, we have partially demonstrated in the present study that tumor cells in metastatic lymph node of colorectal carcinoma still possess cell proliferation activity and metastatic ability in primary site. There may be no association between cell proliferation activity and metastatic ability in colorectal carcinoma.

REFERENCES

1. Mayer RJ, O’Connell MJ, Pepper JE, Wolmanark N. Status of adjuvant therapy for colorectal cancer. J Natl Cancer Inst 1989; 81: 1359-1364

2. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med 1994; 330: 1136-1142

3. Steele G Jr. Advances in the treatment of early- to late-stage colorectal cancer: 20 years of progress. Ann Surg Oncol 1995; 2: 77-88

4. Greene FL, Stewart AK, Norton HJ. A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50, 042 patients. Ann Surg 2002; 236: 416-421

5. Fisher ER, Sasser R, Palekar A, Fisher B, Wolmarck N. Dukes’ classification revisited. Findings from the National Surgical Adjuvant Breast and Bowel Projects (Protocol R-03). Cancer 1989; 64: 2354-2360

6. Douglas HO Jr, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A, Stabléin DM, Bruckner HW. Survival after postoperative combination treatment of rectal cancer. N Engl J Med 1986; 315: 1294-1295

7. Laurie JA, Moertel CG, Fleming TR, Wied HS, Leigh JE, Rubin J, McCormack GW, Gertner JB, Krook JE, Mallard J. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7: 1447-1456

8. Krook JE, Moertel CG, Gunderson LL, Wied HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mallard JA. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715

9. Harris GJ, Church JM, Senagore AJ, Lavice IC, Hull TL, Strong SA, Fazio VW. Factors affecting local recurrence of colonic adenocarcinoma. Dis Colon Rectum 2002; 45: 1029-1034

10. Kanazawa Y, Onda M, Tanaka N, Seya T. Proliferating cell nuclear antigen and p53 protein expression in submucosal invasive colorectal carcinoma. J Nippon Med Sch 2000; 67: 242-249

11. Ondera H, Madani S, Kawamoto K, Kan S, Kondo S, Imamura M. Pathobiologic significance of tumor progression in locally recurrent rectal cancer: different nature from primary cancer. Dis Colon Rectum 2000; 43: 775-781

12. Seong J, Chung EJ, Kim H, Kim KE, Kim NK, Sohn SK, Min JS, Suh CO. Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas. Int J Radiat Oncol Biol Phys 1999; 45: 1167-1173

13. Wielenga VJ, Heider KH, Offerhaus GJ, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST. Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993; 53: 4754-4756

14. Finl L, Dougherty G, Finley G, Meisler A, Bedich M, Cooper DL. Alternative splicing of CD44 pre-mRNA in human colorectal tumors. Biochem Biophys Res Commun 1994; 200: 1015-1022

15. Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL. Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994; 54: 4539-4546

16. Mulder JW, Kruty PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJ, Pals ST. Colorectal cancer prognostic and expression of exons v6-containing CD44 proteins. Lancet 1994; 344: 1470-1472

17. Gottle C, Fawcett J, Walsh MD, Reeder JA, Simmons DL, Antalis TM. Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer. Br J Cancer 1996; 74: 342-351

18. Fukuse T, Hirata T, Tanaka F, Yanagihara K, Hitomi S, Wada H. Prognosis of ipsilateral intrapulmonary metastases in resected nonsmall cell lung cancer. Eur J Cardiothorac Surg 1997; 12: 218-223

19. Ichinoe Y, Hara N, Ohto M. Synchronous lung cancers defined by deoxyribonucleic acid flow cytometry. J Thorac Cardiovasc Surg 1991; 102: 418-424

20. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg 1975; 70: 606-612

21. Nanashima A, Yamaguchi H, Sawai T, Yasutake T, Tsuji T, Jibiki M, Yamaguchi E, Nakagoe T, Ayabe H. Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 1999; 14: 1004-1009

22. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987; 326: 515-517

23. Aruffo A, Stamenkovic I, Meinrick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990; 61: 1303-1313

24. Gunther U, Hofmann M, Rudy W, Reber S, Zoller M, Hausmann I, Matzku S, Wenzel A, Ponta H, Herrlich P. Some tumors, express multiple different CD44 isoforms. Cancer Res 1994; 54: 4539-4546

25. Kanazawa Y, Onda M, Tanaka N, Seya T, Tsuji T, Jibiki M, Yamaguchi E, Nakagoe T, Ayabe H. Expression of adhesion molecules in hepatic metastases of colorectal carcinoma: relationship to primary tumours and prognosis after hepatic resection. J Gastroenterol Hepatol 1999; 14: 1004-1009

26. Simillar MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colon fibroblast. Cancer Res 1981; 41: 1751-1756

27. Fidler IJ. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 1978; 38: 2651-2660

28. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50: 6130-6138

29. Dexter DL, Spremulli EN, Fligel Z, Barbosa JA, Vogel R. Van/voorhes A, Calabresi P. Heterogeneity of cancer cells from a single human colon carcinoma. Am J Med 1981; 71: 949-956

30. Dexter DL, Kowalski HM, Blazar BA, Fligel Z, Vogel R, Hoppener GH. Heterogeneity of tumor cells from a single mouse mammary
31 Bonsing BA, Corver WE, Fleuren GJ, Clenet-Jansen AM, Devilee P, Cornelisse CJ. Allelotype analysis of flow-sorted breast cancer cells demonstrates genetically related diploid and aneuploid subpopulations in primary tumors and lymph node metastases. Genes Chromosomes Cancer 2000; 28: 173-183.

32 Solimene AC, Carneiro CR, Melati I, Lopes JD. Functional differences between two morphologically distinct cell subpopulations within a human colorectal carcinoma cell line. Braz J Med Biol Res 2001; 34: 653-661.

33 Yasoshima T, Denno R, Kawaguchi S, Sato N, Okada Y, Ura H, Kikuchi K, Hirata K. Establishment and characterization of human gastric carcinoma lines with high metastatic potential in the liver: changes in integrin expression associated with the ability to metastasize in the liver of nude mice. Jpn J Cancer Res 1996; 87: 153-160.

34 Samiei M, Waghorne CG. Clonal selection within metastatic SP1 mouse mammary tumors is independent of metastatic potential. Int J Cancer 1991; 47: 771-775.

35 Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH. Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol 2001; 7: 630-636.

36 Price JE, Bell C, Frost P. The use of a genotypic marker to demonstrate clonal dominance during the growth and metastasis of a human breast carcinoma in nude mice. Int J Cancer 1990; 45: 968-971.

37 Suzuki N, Frapart M, Grdina DJ, Meistrich ML, Withers HR. Cell cycle dependency of metastatic lung colony formation. Cancer Res 1977; 37: 3690-3693.

Edited by Zhao M and Wang XL.